Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company's approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate. Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas, distinguishing them from traditional single-asset biotechnology companies.

• Biotechnology organizations are turning in growing numbers to alternative strategies centered on strengthening the performance of already-approved drugs.
• Oncotelic Therapeutics is developing delivery-oriented platforms designed to potentially enhance drug-exposure reliability and overall treatment effectiveness.
• Nanotechnology-enabled drug delivery has become one of the fastest-expanding spaces in oncology therapeutics.
• Oncotelic Therapeutics is also advancing this integrated platform approach through both Deciparticle and PDAOAI, its artificial intelligence-enabled biomedical infrastructure program.
• Across the biotechnology sector, investor interest is increasingly gravitating toward companies that possess differentiated platform technologies with the potential to support a range of drug programs and disease indications.
  
  

Click here to view the custom infographic of the Oncotelic Therapeutics editorial.

Reengineering Familiar Oncology Therapies

The worldwide market for oncology and cancer drugs was valued at $167 billion in 2023 and is forecast to total some $335.2 billion by 2033, advancing at a compound annual growth rate of 7.2% from 2024 through 2033. Key forces underpinning this expansion include a rising global cancer burden alongside continued progress in targeted treatments and immunotherapies that offer more precise and effective options for patients. Nevertheless, shepherding new oncology compounds through clinical development and into the market frequently demands years of trials, considerable capital and substantial regulatory uncertainty.

Because of these barriers, biotechnology organizations are turning in growing numbers to alternative strategies centered on strengthening the performance of already-approved drugs. Instead of engineering entirely new molecular entities, a wide range of companies are investigating advanced delivery technologies with the potential to improve how existing medicines are absorbed, distributed and tolerated inside the human body. This evolution is feeding broader sector interest in delivery-focused platform technologies that may offer shorter development timelines and more manageable commercialization risk than traditional drug discovery approaches.

The problem of therapeutic delivery remains acute throughout oncology. Many precision cancer treatments face obstacles tied to erratic drug delivery, therapeutic resistance and difficulty realizing sufficient exposure within tumor tissues. Advancing delivery efficiency and systemic consistency remains a prominent area of innovation within contemporary cancer medicine.

Researchers are working to confront significant obstacles related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure. Studies show that nanoparticle and targeted drug-delivery approaches are being analyzed with increasing frequency to enhance pharmacokinetics, tumor accumulation and overall treatment efficacy in the oncology space. Additional evaluation indicates that resistance mechanisms and delivery shortcomings continue to pose major challenges for modern oncology, sustaining robust interest in advanced drug-delivery innovation across the field.

Oncotelic Therapeutics is playing a role in this evolving landscape through the development of Sapu003 and its Deciparticle platform. Instead of narrowly pursuing the discovery of wholly new compounds, the company is examining how nanotechnology-driven delivery systems and pharmacokinetic optimization have potential to advance the clinical usefulness of existing therapies. This strategy supports a growing consensus throughout the industry that advancing delivery performance can create significant therapeutic and commercial value.

Sharpening Therapeutic Exposure, Dosing Accuracy

Achieving reliable bioavailability and predictable dosing continues to be a major hurdle for numerous cancer treatments, especially those delivered through oral formulations. Differences in drug absorption, metabolic processing and overall systemic exposure can have a meaningful impact on therapeutic performance, safety profiles and patient results. These considerations are particularly critical for precision-targeted therapies, where maintaining stable drug exposure is often essential for sustaining clinical benefit.

The mTOR-targeting agent everolimus provides a useful example of the pharmacokinetic challenges often encountered with certain therapies. The National Cancer Institute notes that mTOR inhibitors are key in the treatment of multiple cancer types and uncommon disorders, but their use frequently requires careful dose management and ongoing monitoring of drug levels and exposure. Likewise, prescribing information issued by the United States Food and Drug Administration for Afinitor(R), the commercial formulation of everolimus, identifies several variables that can influence drug exposure and contribute to inconsistent absorption in real-world clinical settings.

Increasing emphasis on pharmacokinetic precision is driving increased attention toward intravenous reformulations and advanced delivery technologies designed to enhance dosing reliability and treatment consistency. Research from MarketsandMarkets projects significant long-term growth within the global drug-delivery systems market as pharmaceutical companies invest in approaches intended to improve targeting accuracy, optimize controlled-release capabilities and increase overall drug bioavailability.

Within this evolving landscape, Oncotelic Therapeutics is developing delivery-oriented platforms designed to potentially enhance drug-exposure reliability and overall treatment effectiveness. Through its Deciparticle and Sapu003 programs, the company is contributing to wider industry initiatives focused on refining pharmacokinetic profiles and expanding the clinical value of cancer therapies. The approach reflects a growing view across the sector that advances in drug-delivery design may emerge as an important factor distinguishing next-generation oncology treatment strategies.

Nanotechnology Opens New Treatment Frontiers in Treatment Design

Nanotechnology-enabled drug delivery has become one of the fastest-expanding spaces in oncology therapeutics. Nanoparticle delivery systems are being investigated for their capacity to enhance tissue targeting, strengthen systemic stability and improve intracellular drug delivery while also limiting toxicity and minimizing off-target exposure. These attributes have drawn significant interest from both the scientific community and investors as oncology treatment strategies shift toward increasingly precision-driven approaches.

According to Nature Reviews Drug Discovery, nanoparticle drug-delivery technologies may enhance therapeutic outcomes by improving tumor penetration, enabling more controlled drug release and optimizing pharmacokinetic profiles. Researchers are examining how nanotechnology might overcome delivery barriers that constrain many conventional cancer therapies, including inconsistent absorption and reduced bioavailability often associated with oral administration.

Commercial impetus connected to nanomedicine is also quickly growing. Grand View Research forecasts substantial progress across the global nanomedicine market, projecting an increase from $190 billion in 2023 to more than $410 billion in 2030, as pharmaceutical companies adopt advanced delivery systems for oncology, rare diseases and targeted therapeutics with increasing frequency. Intravenous reformulations and nanoparticle-based delivery are becoming particularly significant as companies pursue greater therapeutic precision and dosing consistency.

Oncotelic Therapeutics is seeking to establish a presence within this expanding area through the advancement of its Deciparticle platform, which is designed to facilitate nanotechnology-based drug delivery across a range of therapeutic uses. The company’s efforts with Sapu003 are consistent with broader industry initiatives aimed at enhancing delivery efficiency and expanding treatment scalability through sophisticated formulation approaches. By emphasizing delivery enhancement, Oncotelic is aligning its strategy with growing pharmaceutical demand for technologies that can increase the value and applicability of existing oncology therapies.

Platform-Based Biotech Approaches Attract Growing Interest

A further transformative shift redefining biotechnology involves the rise of scalable platform-driven models that unite therapeutic development with enabling technologies such as artificial intelligence. AI is taking on an increasingly central role across pharmaceutical research, clinical development and biomarker analysis as companies seek to reduce development timelines and improve the precision of therapeutic targeting.

Artificial intelligence-powered biomedical platforms may contribute to more efficient drug development, refine treatment-targeting strategies and enhance the accuracy of pharmacokinetic prediction models. Consequently, both pharmaceutical organizations and investors are placing greater attention on biotechnology companies that can combine novel therapeutic approaches with scalable technology-driven capabilities.

Platform-oriented development models may also open the door to licensing agreements and a wider range of commercialization opportunities. Instead of relying exclusively on the success of a single therapeutic program, companies with platform-based technologies may have the potential to address multiple applications spanning oncology, rare diseases and precision medicine. This expanded versatility can help diversify development pathways, potentially lowering overall risk while enhancing long-term strategic flexibility.

Oncotelic Therapeutics is also advancing this integrated platform approach through both Deciparticle and PDAOAI, its artificial intelligence-enabled biomedical infrastructure program. Collectively, these initiatives are intended to facilitate broader therapeutic expansion and support data-informed biomedical innovation across oncology and rare disease areas. As a result, the company is positioned where several rapidly growing fields converge, including nanotechnology, cancer therapeutics and AI-driven healthcare technologies.

Markets Follow Rise of Multi-Application Technology Platforms

Across the biotechnology sector, investor interest is increasingly gravitating toward companies that possess differentiated platform technologies with the potential to support a range of drug programs and disease indications. Escalating research and development expenses, combined with extended regulatory pathways, are prompting investors to assess companies not only by the prospects of individual therapeutic candidates but also by the adaptability, scalability and long-term value of their core technology platforms.

This shift mirrors larger developments taking place throughout the pharmaceutical industry. Major drug manufacturers are increasingly pursuing acquisitions and strategic collaborations with emerging companies that offer scalable delivery platforms, AI-driven development capabilities and versatile therapeutic technologies. Solutions that can be applied across multiple disease indications may provide greater long-term commercial opportunities than development efforts centered on a single asset.

Meanwhile, the overall market for drug-delivery technologies continues to experience strong growth. Market analyses from firms such as MarketsandMarkets have identified advanced drug-delivery platforms as a rapidly expanding segment of pharmaceutical innovation, driven by industry efforts to enhance therapeutic precision, improve bioavailability and promote better patient compliance. Increasingly, investors regard these technologies as foundational components in the evolution of precision medicine and next-generation oncology care.

Oncotelic Therapeutics is working to become a presence within this changing market environment through the continued development of Sapu003, Deciparticle and PDAOAI. The company’s approach emphasizes platform-based technologies that have the potential to serve multiple therapeutic uses and support future growth initiatives, rather than depending solely on the success of a single drug program. As momentum continues to build around nanotechnology-driven delivery platforms and AI-powered biomedical innovation, biotechnology companies employing integrated platform strategies like Oncotelic’s may draw increasing interest from both the healthcare sector and the investment community.

Next-Generation Therapeutics Gain Momentum

The biotechnology sector continues to advance beyond traditional drug development, with growing emphasis on innovative therapeutic platforms designed to address complex diseases through novel mechanisms of action. Across oncology, genetic medicine, RNA-based therapeutics and next-generation vaccines, companies are reporting clinical, regulatory and scientific milestones that highlight the industry's focus on developing scalable technologies capable of generating multiple treatment opportunities while improving patient outcomes.

CytoDyn Inc. (OTCQB: CYDY) is reporting the successful enrollment and initial dosing of the first participant in its Expanded Access Program (EAP) for patients with triple-negative breast cancer (TNBC). The company is advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”). The EAP is designed to provide eligible patients access to leronlimab outside of a clinical study setting. The program is intended for patients who have exhausted available treatment options and are not eligible for ongoing or planned clinical studies, in accordance with U.S. Food and Drug Administration (FDA) guidelines.

Revolution Medicines Inc. (NASDAQ: RVMD) has released detailed results from the global, randomized phase 3 RASolute 302 clinical trial. The trial is evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The results were presented during a late-breaking plenary session (LBA5) at the 2026 American Society of Clinical Oncology Annual Meeting and were published  in The New England Journal of Medicine. In the trial, once-daily oral daraxonrasib demonstrated unprecedented improvements in overall survival and progression-free survival compared to standard of care cytotoxic chemotherapy in patients with previously treated metastatic PDAC, with or without an identified tumor RAS mutation. All primary and key secondary endpoints of the trial were met.

Moderna Inc. (NASDAQ: MRNA) has announced a publication in the New England Journal of Medicine of the positive phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. According to the company, mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) has shared the first clinical results from two of its siRNA programs for neuromuscular diseases. According to the company, early results from phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose-dependent muscle exposure, early biomarker effects and favorable tolerability, reinforcing scientific confidence in the potential for differentiated benefits of the αvβ6 integrin-targeted delivery platform. In addition, the company has generated proof-of-concept data, which found that after a single dose, both SRP-1001 and SRP-1003 support reduction, or knockdown, of the target protein or mRNA. In both studies, the majority of adverse events were mild to moderate and were not dose dependent.

These developments underscore the continued evolution of precision medicine and advanced therapeutic platforms, where scientific innovation is increasingly centered on targeted approaches, platform technologies and data-driven development strategies. As clinical programs mature and new modalities demonstrate their potential across multiple disease areas, these advances may help shape the next generation of treatments for patients with significant unmet medical needs.

For more information, visit Oncotelic Therapeutics Inc.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.